Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-3H] scopolamine and acetylcholine at muscarinic receptor subtypes:: Identification of a second allosteric site

被引:99
作者
Lazareno, S
Popham, A
Birdsall, NJM
机构
[1] MRC Technol, London NW7 1AD, England
[2] Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England
关键词
D O I
10.1124/mol.58.1.194
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have studied the interactions of five indolocarbazoles with N-[methyl-H-3] scopolamine (NMS) and unlabeled acetylcholine at M-1-M-4 muscarinic receptors, using equilibrium and nonequilibrium radioligand binding studies. The results are consistent with an allosteric model in which the primary and allosteric ligands bind simultaneously to the receptor and modify each other's affinities. The compounds were generally most active at M-1 receptors. [H-3] NMS binding was enhanced by staurosporine, KT5720, and KT5823 at M-1 and M-2 receptors, and by K-252a at M-1 receptors. Go 7874 reduced [H-3] NMS affinity by up to threefold for all subtypes. A range of cooperative effects with acetylcholine was seen, and, at the M1 receptor, KT5720 had a log affinity of 6.4 and enhanced acetylcholine affinity by 40%. The compounds inhibited the dissociation of [H-3] NMS to different extents across the receptor subtypes, with the largest effects at M-1 receptors. In equilibrium binding studies the inhibitory potency of gallamine at M-1 receptors was not affected by KT5720, indicating that these agents bind to two distinct allosteric sites and have neutral cooperativity with each other. In contrast, gallamine and staurosporine had a negatively cooperative or competitive interaction at M-1 receptors. Similarly, the potency and relative effectiveness of KT5720 for inhibiting [H-3] NMS dissociation from M-1 receptors were not affected by gallamine or brucine, but were affected in a complex manner by staurosporine. These results demonstrate that there are at least two distinct allosteric sites on the M-1 receptor, both of which can support positive cooperativity with acetylcholine.
引用
收藏
页码:194 / 206
页数:13
相关论文
共 21 条
[1]   Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes [J].
Birdsall, NJM ;
Farries, T ;
Gharagozloo, P ;
Kobayashi, S ;
Kuonen, D ;
Lazareno, S ;
Popham, A ;
Sugimoto, M .
LIFE SCIENCES, 1997, 60 (13-14) :1047-1052
[2]  
BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469
[3]   Allosteric interactions at muscarinic cholinoceptors [J].
Christopoulos, A ;
Lanzafame, A ;
Mitchelson, F .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1998, 25 (3-4) :185-194
[4]  
EHLERT FJ, 1988, MOL PHARMACOL, V33, P187
[5]  
ELLIS J, 1992, MOL PHARMACOL, V42, P638
[6]  
Ellis J, 1997, DRUG DEVELOP RES, V40, P193
[7]   Allosteric regulation of the binding of [H-3]acetylcholine to m2 muscarinic receptors [J].
Gnagey, A ;
Ellis, J .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (11) :1767-1775
[8]   Allosteric modulators of ligand binding to muscarinic acetylcholine receptors [J].
Holzgrabe, U ;
Mohr, K .
DRUG DISCOVERY TODAY, 1998, 3 (05) :214-222
[9]   Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors [J].
Jakubik, J ;
Bacakova, L ;
ElFakahany, EE ;
Tucek, S .
MOLECULAR PHARMACOLOGY, 1997, 52 (01) :172-179
[10]   K-252 COMPOUNDS, NOVEL AND POTENT INHIBITORS OF PROTEIN-KINASE-C AND CYCLIC NUCLEOTIDE-DEPENDENT PROTEIN-KINASES [J].
KASE, H ;
IWAHASHI, K ;
NAKANISHI, S ;
MATSUDA, Y ;
YAMADA, K ;
TAKAHASHI, M ;
MURAKATA, C ;
SATO, A ;
KANEKO, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 142 (02) :436-440